Released Mar 18, 2019, after the close
10-Q filed Mar 18, 2019, 46 days after period end · 0001654954-19-002893
Q1 2019 · 10-Q
Revenue$4.57M$4.57M +22.5% vs Q1 2018−19.5% vs Q4 2018
Net Income$471.02K$471.02K N/M vs Q1 2018−85.9% vs Q4 2018
EPS, diluted—
Gross Profit$1,479,060+25.2%
Operating Income$471,020N/M
Operating Cash Flow-$217,712N/M
Free Cash Flowderived-$220,795N/M
Margins · derived
Gross margin32.4%+0.7 pt vs Q1 2018
Operating margin10.3%+76.7 pt vs Q1 2018
Net margin10.3%+81.8 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $4.57M | $3.73M | — | — |
| Net Income | $471.02K | -$2.66M | -$382.14K | $350.01K |
| EPS Diluted | — | -$0.12 | -$0.02 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR